We are live on ! Find out more
GBIO

Generation Bio

Delisted

GBIO was delisted on the 6th of February, 2026.

41 hedge funds and large institutions have $24.2M invested in Generation Bio in 2025 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 12 increasing their positions, 20 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

82% more capital invested

Capital invested by funds: $13.3M → $24.2M (+$10.9M)

52.74% more ownership

Funds ownership: 6.19%58.93% (+53%)

33% less funds holding

Funds holding: 6141 (-20)

40% less repeat investments, than reductions

Existing positions increased: 12 | Existing positions reduced: 20

74% less first-time investments, than exits

New positions opened: 7 | Existing positions closed: 27

Holders
41
Holders Change
-20
Holders Change %
-32.79%
% of All Funds
0.54%
Holding in Top 10
1
Holding in Top 10 Change
+1
Holding in Top 10 Change %
% of All Funds
0.01%
New
7
Increased
12
Reduced
20
Closed
27
Calls
Puts
Net Calls
Net Calls Change
Name Holding Trade Value Shares
Change
Change in
Stake
AVLSA
1
Atlas Venture Life Science Advisors
Massachusetts
$5.07M -$10 -2 -0%
T. Rowe Price Associates
2
T. Rowe Price Associates
Maryland
$3.53M -$1.4M -269,472 -32%
Renaissance Technologies
3
Renaissance Technologies
New York
$2.11M +$446K +86,185 +33%
SL
4
Siren LLC
Connecticut
$1.82M -$5 -1 -0%
Vanguard Group
5
Vanguard Group
Pennsylvania
$1.41M -$10 -2 -0%
Marshall Wace
6
Marshall Wace
United Kingdom
$1.34M +$1.07M +206,841 +1,780%
BBA
7
Baker Bros. Advisors
New York
$1.19M -$10 -2 -0%
Morgan Stanley
8
Morgan Stanley
New York
$1.01M +$378K +72,987 +80%
UBS Group
9
UBS Group
Switzerland
$910K +$312K +60,231 +68%
Acadian Asset Management
10
Acadian Asset Management
Massachusetts
$779K +$21.5K +4,159 +3%
Goldman Sachs
11
Goldman Sachs
New York
$726K +$63.1K +12,174 +11%
YCM
12
Yiheng Capital Management
California
$646K -$16 -3 -0%
CF
13
Cantor Fitzgerald
New York
$606K +$513K +99,000 New
Millennium Management
14
Millennium Management
New York
$596K -$45.6K -8,807 -8%
Bank of America
15
Bank of America
North Carolina
$519K -$12.3K -2,378 -3%
BlackRock
16
BlackRock
New York
$368K -$290K -56,042 -48%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$305K -$16 -3 -0%
Citadel Advisors
18
Citadel Advisors
Florida
$289K +$145K +27,981 +146%
TD Asset Management
19
TD Asset Management
Ontario, Canada
$163K -$38.1K -7,361 -22%
ACM
20
ADAR1 Capital Management
Texas
$136K +$115K +22,144 New
State Street
21
State Street
Massachusetts
$122K -$3.21K -619 -3%
PAI
22
Palo Alto Investors
California
$92.1K -$5 -1 -0%
Manulife (Manufacturers Life Insurance)
23
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$88.1K
Northern Trust
24
Northern Trust
Illinois
$81.4K -$16 -3 -0%
Fidelity Investments
25
Fidelity Investments
Massachusetts
$79.8K -$1.15M -221,531 -94%

GBIO Hedge Fund Activity: Q3 2025 in Review

41 of the 7,628 institutional investors tracked by Wall St. Rank reported a position in Generation Bio (GBIO) for Q3 2025, worth a combined $24.2M — up 82% from $13.3M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of GBIO and 7 opened new positions — a net loss of 20 holders — while 20 trimmed existing stakes and 12 added.

The largest buyer was Marshall Wace, adding an estimated $1.07M. The largest seller was T. Rowe Price Associates, cutting an estimated $1.4M.

  • 41 institutional investors held Generation Bio (GBIO) as of Q3 2025, down from 61 in Q2 2025.
  • Funds reported $24.2M of Generation Bio stock for Q3 2025, up 82% quarter-over-quarter.
  • 7 funds opened new Generation Bio positions in Q3 2025 and 27 closed out, a net change of -20 holders.
  • The largest Generation Bio buyer in Q3 2025 was Marshall Wace, an estimated $1.07M added.
  • The largest Generation Bio seller in Q3 2025 was T. Rowe Price Associates, an estimated $1.4M sold.

Based on aggregated 13F filings for Q3 2025.